Consensus CG Oncology, Inc.

Equities

CGON

US1569441009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
25.84 ^USD	-9.33%		-26.38%	0.00%

May. 09	CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 03	CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin	CI

Evolution of the average Target Price on CG Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a6257ccd249585defced.c0AXvifzm4YbMeXSdURmN4kjDmEnlJaOqLzGRI5wqf8.MHB2iXiVzOMuS7GUDSkTUsJCOlR00vfD4u6pHrc175YDKEbkTJXozylJoA~e0eecff7fb9b67e2f61ca19b48dcd7c5

Analyst Recommendations on CG Oncology, Inc.

Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target	Feb. 20	MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target	Feb. 20	MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55	Feb. 20	MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target	Feb. 14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.84 USD

Average target price

66.8 USD

Spread / Average Target

+158.51%

High Price Target

86 USD

Spread / Highest target

+232.82%

Low Price Target

43 USD

Spread / Lowest Target

+66.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CG Oncology, Inc.

Goldman Sachs
Cantor Fitzgerald
Morgan Stanley
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar